Market research
B9A.F BioArctic AB (publ)
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- 144.86
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.68
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- SE0010323311
- Market cap
- 3B
- P/E ratio
- 144.86
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.68
About
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment. Further, it is developing Lecanemab for Subcutaneous treatment, which is in registration stage; lecanemab, which is in phase 3 clinical trials for presymptomatic treatment; Exidavnemab, which is in phase 2 clinical trials; Lecanemab back-up, BAN2803, ND3014, and BAN2802 that are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, PD-BT2238 which are in research stage. The company has research and collaboration agreement with Eli Lilly to develop a new drug candidate combining the BrainTransporter technology with a Lilly proprietary molecule. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the B9A.F discussion.
5 years, 5 months ago
BioArctic AB (publ) is currently in a long term uptrend where the price is trading 53.9% above its 200 day moving average.
From a valuation standpoint, the stock is 90.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 129.1.
BioArctic AB (publ)'s total revenue sank by 68.4% to $8M since the same quarter in the previous year.
Its net income has increased by 22.8% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.9% to $-34M since the same quarter in the previous year.
Based on the above factors, BioArctic AB (publ) gets an overall score of 4/5.